Agios Pharm (AGIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Agios Pharm (AGIO) has a cash flow conversion efficiency ratio of -0.107x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-118.92 Million) by net assets ($1.11 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check strategic asset allocation of Agios Pharm to assess the company's strategic physical and investment asset allocation.
Agios Pharm - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Agios Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. See AGIO total equity for net asset value and shareholders' equity analysis.
Agios Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Agios Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PLUXEE NV
PA:PLX
|
0.434x |
|
Suning Commerce Group Co Ltd
SHE:002024
|
0.015x |
|
BIEM.L .FDLKK Garment Co Ltd
SHE:002832
|
0.029x |
|
Xian Xice Testing Technology Co. Ltd. A
SHE:301306
|
N/A |
|
nCino Inc
NASDAQ:NCNO
|
0.012x |
|
Taysha Gene Therapies Inc
NASDAQ:TSHA
|
-0.193x |
|
Choice International Limited
NSE:CHOICEIN
|
-0.037x |
|
Grand City Properties SA
XETRA:GYC
|
0.013x |
Annual Cash Flow Conversion Efficiency for Agios Pharm (2011–2025)
The table below shows the annual cash flow conversion efficiency of Agios Pharm from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Agios Pharm.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.19 Billion | $-372.98 Million | -0.313x | -23.57% |
| 2024-12-31 | $1.54 Billion | $-389.84 Million | -0.253x | +30.70% |
| 2023-12-31 | $811.02 Million | $-296.06 Million | -0.365x | -29.85% |
| 2022-12-31 | $1.10 Billion | $-309.48 Million | -0.281x | +10.83% |
| 2021-12-31 | $1.29 Billion | $-407.32 Million | -0.315x | +56.68% |
| 2020-12-31 | $399.50 Million | $-290.76 Million | -0.728x | -25.78% |
| 2019-12-31 | $640.53 Million | $-370.62 Million | -0.579x | -30.68% |
| 2018-12-31 | $687.54 Million | $-304.42 Million | -0.443x | +41.71% |
| 2017-12-31 | $375.50 Million | $-285.23 Million | -0.760x | -806.36% |
| 2016-12-31 | $358.59 Million | $38.56 Million | 0.108x | +148.23% |
| 2015-12-31 | $345.12 Million | $-76.95 Million | -0.223x | -59.42% |
| 2014-12-31 | $424.37 Million | $-59.35 Million | -0.140x | +67.39% |
| 2013-12-31 | $131.48 Million | $-56.40 Million | -0.429x | +62.00% |
| 2012-12-31 | $43.90 Million | $-49.55 Million | -1.129x | -368.27% |
| 2011-12-31 | $63.14 Million | $-15.22 Million | -0.241x | -- |
About Agios Pharm
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment… Read more